Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Ironwood Pharmaceuticals Inc's Business Segments
Ironwood Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
4
Largest Segment
Canada and Mexico
Total Revenue
$ 113
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Canada and Mexico1.6%
- Royalty Canada and Mexico AbbVie Plc0.6%
- Royalty0.2%
- Collaborative Arrangement Collaboration and License Agreements0.1%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Canada and Mexico | $ 2 | 1.6% |
| Royalty Canada and Mexico AbbVie Plc | $ 1 | 0.6% |
| Royalty | $ 0 | 0.2% |
1 more segments available
Sign in to unlock the full Ironwood Pharmaceuticals Inc dataset.
Annual Results
Revenue Share by Reportable Segment - FY
- Canada and Mexico1.6%
- Royalty Canada and Mexico AbbVie Plc0.6%
- Royalty0.2%
- Collaborative Arrangement Collaboration and License Agreements0.1%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Canada and Mexico | $ 2 | 1.6% |
| Royalty Canada and Mexico AbbVie Plc | $ 1 | 0.6% |
| Royalty | $ 0 | 0.2% |
1 more segments available
Sign in to unlock the full Ironwood Pharmaceuticals Inc dataset.
Description of Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals Inc. is an American pharmaceutical company, founded in 1998, and is headquartered in Cambridge, Massachusetts. The company specializes in the development and commercialization of drugs to treat gastrointestinal disorders, including irritable bowel syndrome, acid reflux, and refractory gastroesophageal reflux disease.
Ironwood Pharmaceuticals Inc. has a broad range of products that are used in the treatment of gastrointestinal disorders, including medications like Linzess, Zelnorm, and Zurampic. Ironwood's lead product, Linzess, is approved by the FDA for the treatment of both irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). It works by regulating the activity of specific receptors in the gut, improving motility and reducing pain.
Ironwood Pharmaceuticals Inc. is committed to developing innovative solutions for gastrointestinal disorders. As such, it is actively involved in the research and clinical development of potential new treatments to address unmet medical needs. In 2014, Ironwood Pharmaceuticals Inc. entered into a strategic collaboration with AstraZeneca to develop and commercialize lesinurad, a potential treatment for gout.
Ironwood Pharmaceuticals Inc. has a dedicated team of over 500 employees who work together to advance the company's vision of transforming the treatment of gastrointestinal disorders. The company has a history of investing in research and development, and as of 2021, had over 150 patents and patent applications in the United States.
Ironwood Pharmaceuticals Inc. is also committed to giving back to the community. In 2020, the company announced a donation of $1 million to support organizations working to address racial injustice and health disparities in the United States.
In conclusion, Ironwood Pharmaceuticals Inc. is a pharmaceutical company focused on developing treatments for gastrointestinal disorders. With a broad range of products, a strong portfolio of patents, and a commitment to innovation and community engagement, Ironwood Pharmaceuticals Inc. is well-positioned to make a positive impact on the lives of patients with gastrointestinal disorders.
Ironwood Pharmaceuticals Inc. has a broad range of products that are used in the treatment of gastrointestinal disorders, including medications like Linzess, Zelnorm, and Zurampic. Ironwood's lead product, Linzess, is approved by the FDA for the treatment of both irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). It works by regulating the activity of specific receptors in the gut, improving motility and reducing pain.
Ironwood Pharmaceuticals Inc. is committed to developing innovative solutions for gastrointestinal disorders. As such, it is actively involved in the research and clinical development of potential new treatments to address unmet medical needs. In 2014, Ironwood Pharmaceuticals Inc. entered into a strategic collaboration with AstraZeneca to develop and commercialize lesinurad, a potential treatment for gout.
Ironwood Pharmaceuticals Inc. has a dedicated team of over 500 employees who work together to advance the company's vision of transforming the treatment of gastrointestinal disorders. The company has a history of investing in research and development, and as of 2021, had over 150 patents and patent applications in the United States.
Ironwood Pharmaceuticals Inc. is also committed to giving back to the community. In 2020, the company announced a donation of $1 million to support organizations working to address racial injustice and health disparities in the United States.
In conclusion, Ironwood Pharmaceuticals Inc. is a pharmaceutical company focused on developing treatments for gastrointestinal disorders. With a broad range of products, a strong portfolio of patents, and a commitment to innovation and community engagement, Ironwood Pharmaceuticals Inc. is well-positioned to make a positive impact on the lives of patients with gastrointestinal disorders.
Ironwood Pharmaceuticals Inc. is a prominent player in the pharmaceutical industry, focused on developing and commercializing innovative therapies primarily for gastrointestinal (GI) conditions, as well as a range of other health issues. The company emphasizes its commitment to improving patient outcomes through robust research and development, strategic partnerships, and comprehensive support services. Below is an extensive overview of Ironwoods segments, products, and services.
Segments
1. Gastrointestinal Portfolio:
Ironwoods GI segment is its cornerstone, featuring a portfolio of medications specifically targeting various gastrointestinal diseases. This segment emphasizes conditions like irritable bowel syndrome (IBS) and chronic constipation, where innovative therapies are essential.
2. Research & Development (R&D):
The company dedicates significant resources to R&D, focusing on innovative drug discovery and development. This segment aims to enhance existing therapies and develop new treatment modalities for unmet medical needs within the GI space and beyond.
3. Partnered Products:
Ironwood engages in strategic collaborations with other pharmaceutical companies and organizations to co-develop and commercialize drugs. This segment is crucial for expanding their product offerings and leveraging external expertise and resources.
Products
1. LINZESS (linaclotide):
- Indication: A therapeutic option for adults with IBS-C and chronic idiopathic constipation (CIC).
- Mechanism: LINZESS works by increasing the secretion of chloride and water in the intestinal lumen, facilitating bowel movements and alleviating discomfort associated with these conditions.
2. Zurampic (lesinurad):
- Indication: Approved for the treatment of hyperuricemia associated with gout in combination with a xanthine oxidase inhibitor.
- Mechanism: Zurampic functions by inhibiting the urate transporter, enhancing urinary excretion of uric acid to lower serum urate levels.
3. Duzallo (combination of allopurinol and lesinurad):
- Indication: Specifically formulated for patients with gout who require additional control of uric acid levels.
- Mechanism: Combining allopurinol, a xanthine oxidase inhibitor, with lesinurad provides a dual mechanism of action for lowering uric acid levels effectively.
4. Olinciguat:
- Indication: A novel therapeutic candidate designed to treat various vascular diseases, though currently in clinical development.
- Mechanism: Olinciguat acts as a soluble guanylate cyclase (sGC) stimulator, promoting vasodilation and addressing the underlying pathophysiology of vascular-related conditions.
Services
1. Patient Support Programs:
Ironwood Pharmaceuticals is committed to enhancing patient experiences through various support programs. These initiatives include financial assistance, education on medication management, and resources for navigating treatment journeys.
2. Healthcare Professionals Resources:
Ironwood provides educational resources, training, and tools for healthcare professionals. This support ensures that providers can offer effective treatments and understand the complexities of the medications they prescribe.
3. Clinical Trial Services:
The company facilitates clinical research by offering services that include protocol development, site management, and patient recruitment. These services aim to speed the development of new therapies and ensure rigorous standards are met throughout the trial process.
4. Healthcare System and Payer Support:
Ironwood collaborates with healthcare providers and payers to ensure patient access to its therapies. This involves working with insurers to establish coverage and reimbursement pathways while also providing data to demonstrate the value of their treatments.
In summary, Ironwood Pharmaceuticals Inc. stands out as a leading pharmaceutical company with a significant focus on innovative GI treatments and a diverse array of products and services. Their commitment to research, patient support, and collaborative partnerships distinguishes them in the pharmaceutical landscape, addressing critical health needs and enhancing patient care in both GI and other therapeutic areas.
Segments
1. Gastrointestinal Portfolio:
Ironwoods GI segment is its cornerstone, featuring a portfolio of medications specifically targeting various gastrointestinal diseases. This segment emphasizes conditions like irritable bowel syndrome (IBS) and chronic constipation, where innovative therapies are essential.
2. Research & Development (R&D):
The company dedicates significant resources to R&D, focusing on innovative drug discovery and development. This segment aims to enhance existing therapies and develop new treatment modalities for unmet medical needs within the GI space and beyond.
3. Partnered Products:
Ironwood engages in strategic collaborations with other pharmaceutical companies and organizations to co-develop and commercialize drugs. This segment is crucial for expanding their product offerings and leveraging external expertise and resources.
Products
1. LINZESS (linaclotide):
- Indication: A therapeutic option for adults with IBS-C and chronic idiopathic constipation (CIC).
- Mechanism: LINZESS works by increasing the secretion of chloride and water in the intestinal lumen, facilitating bowel movements and alleviating discomfort associated with these conditions.
2. Zurampic (lesinurad):
- Indication: Approved for the treatment of hyperuricemia associated with gout in combination with a xanthine oxidase inhibitor.
- Mechanism: Zurampic functions by inhibiting the urate transporter, enhancing urinary excretion of uric acid to lower serum urate levels.
3. Duzallo (combination of allopurinol and lesinurad):
- Indication: Specifically formulated for patients with gout who require additional control of uric acid levels.
- Mechanism: Combining allopurinol, a xanthine oxidase inhibitor, with lesinurad provides a dual mechanism of action for lowering uric acid levels effectively.
4. Olinciguat:
- Indication: A novel therapeutic candidate designed to treat various vascular diseases, though currently in clinical development.
- Mechanism: Olinciguat acts as a soluble guanylate cyclase (sGC) stimulator, promoting vasodilation and addressing the underlying pathophysiology of vascular-related conditions.
Services
1. Patient Support Programs:
Ironwood Pharmaceuticals is committed to enhancing patient experiences through various support programs. These initiatives include financial assistance, education on medication management, and resources for navigating treatment journeys.
2. Healthcare Professionals Resources:
Ironwood provides educational resources, training, and tools for healthcare professionals. This support ensures that providers can offer effective treatments and understand the complexities of the medications they prescribe.
3. Clinical Trial Services:
The company facilitates clinical research by offering services that include protocol development, site management, and patient recruitment. These services aim to speed the development of new therapies and ensure rigorous standards are met throughout the trial process.
4. Healthcare System and Payer Support:
Ironwood collaborates with healthcare providers and payers to ensure patient access to its therapies. This involves working with insurers to establish coverage and reimbursement pathways while also providing data to demonstrate the value of their treatments.
In summary, Ironwood Pharmaceuticals Inc. stands out as a leading pharmaceutical company with a significant focus on innovative GI treatments and a diverse array of products and services. Their commitment to research, patient support, and collaborative partnerships distinguishes them in the pharmaceutical landscape, addressing critical health needs and enhancing patient care in both GI and other therapeutic areas.